PL
Prof Serigne N Lo
Melanoma Institute Australia, The University of Sydney, Geneva University, University of Geneva, Université Cheikh Anta Diop Faculté des Sciences et Techniques
Research areas: Medicine · Oncology · Cutaneous Melanoma Detection and Management · Melanoma and MAPK Pathways · Cancer Immunotherapy and Biomarkers
0000-0001-5092-5544
Employment
- 2015 - Present
-
The University of Sydney Professor of Biostatistics2012 - Present
Education
-
Geneva University PhD2003 - 2006
-
Université de Genève Diplôme d'Economie Approfondie en Econométrie2000 - 2002
-
Université Cheikh Anta Diop Faculté des Sciences et Techniques DEUG math-physics1994 - 1997
Projects & Funding
Projects & funding information is unavailable.
Publications (609)
- Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-risk resected melanoma: a multicenter international retrospective study. Save
- Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Save
- On a Penalized Likelihood Approach for Joint Modeling of Longitudinal Covariates and Partly Interval‐Censored Data—An Application to the Anti‐PD1 Brain Collaboration Trial Save
- Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma Save
- Specialist-Centre Radiotherapy and Oncological Outcomes in Extremity Soft Tissue Sarcoma: A Registry-Based Cohort Study Save
- Uptake of sentinel lymph node biopsy following a melanoma diagnosis: an Australian population-based study Save
- Staging and prognosis of mucosal melanomas of the head and neck Save
- Validation of the Melanoma Institute Australia Prediction Tool for Sentinel Node Metastasis Risk Amongst Patients with Cutaneous Head and Neck Melanoma Save
- Correction to Lancet Oncol 2026; 27: 452–60 Save
- Time trends in the incidence of multiple primary melanomas in Australia Save
- 74473 Revisiting the Multicenter Selective Lymphadenectomy Trial-I in the modern era: undergoing sentinel lymph node biopsy is associated with overall survival benefit in cutaneous melanoma Save
- Revisiting the Multicenter Selective Lymphadenectomy Trial-I in the modern era:undergoing sentinel lymph node biopsy is associated with overall survival benefit in cutaneous melanoma Save
- Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience Save
- Utility of recurrence-based surrogate endpoints for survival in adjuvant cancer trials: evidence from melanoma Save
- A phase 2 study of neoadjuvant nivolumab (nivo) + relatlimab (rela) in high-risk stage II cutaneous melanoma (NeoReNi). Save
- A phase 3, international, multicenter, randomized, controlled trial of selective index lymph node resection versus therapeutic lymph node dissection after neoadjuvant immunotherapy for stage IIIB-D melanoma (MSLT-3/S2601/EORTC2519). Save
- A propensity score-matched analysis comparing first-line regional, systemic, and intralesional treatments for melanoma in-transit metastases in a contemporary patient population. Save
- Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts). Save
- NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy. Save
- Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates. Save